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:ةساردلا فده.ضشًنا ازْ صٛخشح ٙف ِسٔدٔ َٙاطبنا ٙئاعٕنا ًُٕنا مياعٔ تَاثًنا ٌاطشس ضشي ٍٛب تقلاعنا دادٚإ 
:ثحبلا ةيجهىم جٚشخأ ٌاسَٛ ٍي ةشخفهن  ٙكهًنا ٗفشخسًنا ٙف ٙخٕنٕثابنا ىسق ٙف اَٛاطٚشب ٙف تٛناحنا تساسذنا2112  بآ تٚاغنٔ2113 
 ىْدذع غنابنا تَاثًنا ٌاطشس ضشًب ٌٕباصًنا ٍٛٛقاشعنا سٕكزنا ٗظشًنا ٍي ةرٕخأًنا وذنا ثاُٛع ٗهع42  ءاحصأ ٍٚشخآٔ طٚشي
 ىْدذع33 .ةشطٛس تعًٕدًك إيذخخسا 
 لئاسولاةيئاصحلإا( واظَ واذخخسا ىح:SPSS .اٛئاصحإ حئاخُنا مٛهحخن ٘شحٕٛبيٕكنا ) 
 جئاتىلا(تٛناع تُٕٚعي ةداٚص تٛناحنا تساسذنا حئاخَ ثشٓظأ:p < 1.15 تَساقي ٗظشًنا ٖذن َٙاطبنا ٙئاعٕنا ًُٕنا مياع ٖٕخسي ٙف )
.ةشطٛسنا تعًٕدًب 
تاجاتىتسلااجاخُخسلاا ىح تٛناحنا تساسذنا للاخ ٍي :  تَاثًنا ٌاطشس ضشًن صٛخشح مياعك َٙاطبنا ٙئاعٕنا ًُٕنا مياع داًخعا ٌاكيلإاب
.ضشًنا ٍي ةشكبًنا محاشًنا ٙف اًٛسلا 
تايصوتلا :1-  ثاشٛٛغخنأ َٙاطبنا ٙئاعٕنا ًُٕنا مياع ٍٛب تقلاعنا تفشعًن تيذقخي تُٛٛخ تساسد ءاشخإ تٛناحنا تساسذنا للاخ ٍي ٗصٕٚ ذق
ًنا ٌاطشسن تُٛٛدنا  .تَاث2- .ّثٔذحب ؤبُخهن ضشًنا سٕٓظ تٚاذب ٙف تَاثًنا ٌاطشسب ٌٕباصًنا ٗظشًهن ِلاعأ سٕكزًنا مياعنا ساٛق ءاشخإ 
Abstract: 
Objective: The aim of this work is to study the alterations in the vascular endothelial growth factor 
(VEGF-A), and its role in pathogenicity of bladder cancer in serum of men who are initially diagnosed 
with this disease. 
Methods: The current study was applied in pathology department of British United Kingdom kings 
college hospital during April 2112 to August 2113 by using Enzyme Linked Immuno Assay (ELISA)  on  
serum taken from 42 men infected with  bladder cancer , and other 33 benign considered as a control 
group to detect vascular endothelial growth factor type A (VEGF-A). 
Data analysis: SPSS computerizing system has been used for statistically analysis of data. 
Results: The results revealed a highly significant (P<1.15) level of  VEGF-A in serum of patients in 
comparison with the control group. 
Conclusion:It was concluded from the results of the present study that VEGF-A was good prognostic 
biomarker for urinary bladder cancer in men ,and these results significantly correlate with   the early 
stages of disease.  
Recommendation : It may be recommended that using VEGF-A to predict and diagnosis the bladder 
cancer. 
Key words:VEGF-A, bladder cancer. 
INTRODUCTION: 
Vascular endothelial growth factor (VEGF) is a chemical signal produced by 
cells that stimulates the growth of new blood vessels (1).It is part of the system that 
restores the oxygen supply to tissues when blood circulation is inadequate (2). VEGF's 
normal function is to create new blood vessels during embryonic development, new 
blood vessels after injury, and new vessels (collateral circulation) to bypass blocked 
vessels. When VEGF is over expressed, it can contribute to disease. Solid cancers 
cannot grow beyond a limited size without an adequate blood supply; cancers that can 
express VEGF are able t grow and metastasize (3). VEGF is a sub. Family of growth 
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factors, specifically the platelet. Derived growth factor family of cystine. knot growth 
factors, they are important signaling proteins involved in both vasculogenesis (the ''de 
novo'' formation of the embryoniccirculatory system)and angiogenesis (the growth of 
blood vessels from pre.existing vasculature  (4). 
''In vitro'', VEGF-A has been shown to stimulate endothelial cell mitogenesis and 
cell migration (Jones et al; 2111). VEGF-A is also a vasodilator and increases 
microvascular permeability and was originally referred to as vascular permeability fact 
(5,6). The VEGF receptors have an extracellular portion consisting of  7 
immunoglobulin. Like domains, a single transmembrane spanning region, and an 
intracellular portion containing a split tyrosine. kinase domain , VEGF-A binds to 
VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1), VEGFR-2 appears to mediate almost all 
of the known cellular responses to VEGF(7) . The function of VEGFR-1 is less 
well.defined, although it is thought to modulate VEGFR.2 signaling, another function of 
VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-
2 binding,VEGF.C and VEGF.D, but not VEGF-A, are ligands for a third receptor 
(VEGFR-3)(3 ,9). 
AIM OF STUDY: 
To study the alterations in the VEGF-A in serum of men who are initially diagnosed 
with bladder cancer. Also in trying to measure the factor in future diagnosis for bladder 
carcinoma. 
PATIENTS AND METHODS: 
The current study included 42 patients of Iraqi males with urinary bladder 
carcinoma and 33 other healthy groups adjusted as control group. The blood were drawn 
to get the serum  from the patients when coming to operation hall for cystoscopically 
checking and treating at AL-Sader medical city hospital in AL-governorate Najaf during 
period from April 2112 until August 2113. The patients group were classified into four 
stages and three grades, the stages are Ta,T1,T2,T3, and the grades are I,II,III (WHO, 
2111),also into four subgroups according to ages (41.49Y),(51.59Y), (61.69Y) 
,(71.31Y) ,and two other subgroups smokers and non smokers. 
The vascular endothelial growth factor.A(VEGF-A)  ELISA Assay 
 
Figure (1):microwells of VEGF.A test with developing color. Figure(5 ):VEGF.A standard curve. 
 
This assay is based on the formation of coloured product in proportion to the 















VEGF-A concentration ng/ml 
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by addition of acid and absorbance is measured at 451nm. The specific Kit for this test 
is supplied by (eBioscience Company , Inc. Campus Vienna Biocenter 21131 Vienna, 
Austria.human VEGF.A platinum   ELISA.BMS277/2/BMS277/2TEN). 
RESULTS: 
1- The vascular endothelial growth factor level (VEGF-A). 
 
Figure(3):Comparison between VEGF-A level and control. 
 
Serum analysis of VEGF-A levels revealed there was statistically significant 
increase (p<1.15) in urinary bladder cancer patients (1.55±1.29) in comparison with the 
control group(1.17±1.31) as in (Figure3). 
5-Comparison between VEGF-A levels and stages of tumor. 
 
 
Figure (4)Comparison between VEGF-A level and stages. 
 
There were statistically significant differences(p<1.15)  in the levels of VEGF-A 
between stages of bladder cancer patients ,significant increased(p<1.15)in T3(2.19±1.6) 
compared with Ta(1.91±1.23),T1(1.14±1.13) and T2(1.64±1.9) as shown in(Fig 4 ). 
3-Comparison between VEGF-A  levels and  grades of tumor.          
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Figure(5):Comparison between VEGF-A level and grades. 
 
The statistic analysis shows significant differences (p<1.15)  in the levels of  VEGF-A 
between grades of bladder cancer patients, significant increased(p<1.15)in VEGF-A 
level in GIII (1.34±1.44) compared with GI(1.73±1.23), and GII (1.23±1.33) (Fig 5). 
4-Comparison between VEGF-A levels  according to ages. 
 
Figure(6):Comparison between VEGF-A level and ages. 
 
 Figure(6),shows acomparison between VEGF-A level in the different groups of bladder 
cancer patients according to their ages.This result revealed the significant increased 
(p<1.15) in the levels of VEGF-A at all ages, highly significant increase(p<1.15) of(71-
31Y) (2.4±1.73) . 
5-Comparison between VEGF-A levels  and  to smoking: 
 
Figure (7):Comparison between VEGF-A level and smoking. 
 
The mean values and the standard errors of smokers and non smokers groups of 
bladder cancer patients are shown in figure(7),this result demonstrate statistically 
significant increased(p<1.15) in serum VEGF-A level (p<1.15) in non-smokers 
(1.75±1.59) compared with the smokers (1.49±1.34) . 
DISCUSSION: 
The present study result  in Figure (3), revealed a significant increase(p< 1.15) in 
serum VEGF of  urinary bladder cancer patients in comparison with the control.Many 
studies indicated that VEGF was the important angiogenic factor that play a vital role in 
the development and progression of tumor(11 ,11).Previous study of Rahmani (12) 
contributed high expression  of VEGF to  malignant tumor and its promotion to tumor 
progression. VEGF is the key mediator of angiogenesis ,where it is up regulated by 
oncogenic expression and variety of growth factors also apotent stimulator of an 
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angiogenesis, inducer of endothelial cell migration and vascular 
permeability(13,14).Studies of Jelkmann(15) and Mylona (16) investigated VEGF as a 
prognostic serum marker in urinary bladder carcinoma and various types of cancer 
including astrointestinal, hepatobiliary,renal,and ovarian cancers.                                                                                                       
Many studies indicated a VEGF as a prognostic marker in many types of  
human cancer such as gastric carcinoma, colorectal carcinoma, lung cancer, 
breast cancer, ovarian cancer, and pancreatic cancer (17,13). Two reports 
suggested that VEGF-C have basis functions of malignant cells and 
proliferation and apoptosis(19).Most studies that used serum or plasma samples 
confirmed increasing of free VEGF in malignant disease(15).The serum and 
plasma has been reported VEGF to be more correlated in cancer patients(21). 
         The Figure (4), (5) showed a significant increase (p<1.15) in serum 
VEGF in high stage and grade of urinary bladder patients. Study of Vdeira (21) 
revealed the highly expression of VEGF. A was in the non muscle. Invasive 
bladder cancer cells (NMIBC). Other studies indicated that VEGF protein 
significantly over. expressed in all grades and stages of TCC (22).Other study 
showed the VEGF.A transcript levels were greater in cancer tissues than in 
normal urothelium and more significantly in stages (T2-T4) than in stages 
(Ta,T1) urothelial tumors(23).Study of Swellam (4) revealed a significant 
elevation of VEGF in late stage compared with early ones contributed that to 
direct angiogenic effect of the growth factor and proteolytic enzymes such as 
urokinase. type plasminogen activator in endothelial cells. Further studies 
showed that VEGF also appears to be a significant prognostic formation in 
association with tumor grade and average of apoptotic cells(24). 
         The older ages of current study represented in Figure (6) explained highly 
significant differences in serum VEGF level in patients of urinary bladder 
cancer. Previous study of Horstmann (25) showed that age of 51-71 years has a 
peak incidence of bladder cancer and contributed the reason for cumulative 
effects of long time exposure to carcinogens, and failure of DNA repair 
mechanism with aging. 
         The smokers patients of urinary bladder cancer represented in Figure 
(7)showed a highly elevation of serum VEGF in smokers  than non-smokers 
patients. Study of Rizvi(26) suggested a correlation between apoptosis with 
smoking and a risk of bladder cancer. Study of Baris (27) proved that cigarette 
smoking stimulate apoptosis through a mechanism involving in the release of 
apoptotic related protein. 
CONCLUSIONS: 
High levels of vascular endothelial growth factor were detected in serum of men with 
bladder cancer indicating the important role of this marker as prognostic factor for this 
disease. 
RECOMMENDATIONS: 
1. Advanced study focusing on genetic DNA analysis of biomarker gene of bladder 
carcinoma patients to study the relationship between this biomarker proteins and the 
gene amplification. 
2. It may be recommended that, using this biomarker to predict and diagnosis the 
bladder cancer. 
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